(Date:12/14/2009)... Boston Scientific Corporation (NYSE: BSX ) today ... billion aggregate principal amount of its senior notes under ... consists of $850 million of 4.50 percent notes due ... January 2020 and $300 million of 7.375 percent notes ... the net proceeds for general corporate purposes, including prepaying ...
(Date:12/14/2009)... ThermoFab, a US-based thermoforming company, has completed the delivery of ... sheet metal to a plastic enclosure with a smaller footprint ... ... Shirley, MA (PRWEB) December 14, 2009 -- ThermoFab, a US-based ... Flow Tester – helping Brookfield move from sheet metal to ...
(Date:12/11/2009)... 10, 2009 miRagen Therapeutics, Inc., a biopharmaceutical ... innovative microRNA-based therapeutics for cardiovascular and muscle disease, ... microRNA-206 (miR-206) plays a crucial role in the ... Gehrig,s disease) and in neuromuscular synaptic regeneration in ... 11 issue of the journal Science , ...
(Date:12/11/2009)... ASA (OSE: ALGETA), the,cancer therapeutics company, announces ... the Tulane Cancer Center, New Orleans, has ... study of Alpharadin in men with,castration-resistant (also ... metastasized to the skeleton. , ... Prostate CAncer) study is a,double-blind, randomized, controlled ...
Breaking Biology Technology:Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4... Novavax, Inc.,(Nasdaq: NVAX ) and the ... from a preclinical study of a Respiratory Syncytial ... worldwide rights from the, University of Massachusetts Medical ... commercialization of Paramyxovirus vaccines incorporating,certain Virus-Like-Particles ("VLPs"). ...
... NOVATO, Calif., Dec. 9 BioMarin Pharmaceutical,Inc. ... that its partner Merck Serono, a division,of ... approval for,Kuvan(R) (sapropterin dihydrochloride) for the treatment ... deficient patients,from the European Commission. Merck ...
... favorable results from a Phase 1 vehicle-controlled study of ... during urological surgery. , , ... patients undergoing endoscopic removal of urinary stones, and was ... the drug product. The pharmacokinetic data from this study ...
Other Biology Technology:NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate 2NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate 3NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate 4Kuvan Receives Marketing Approval in the European Union 2Kuvan Receives Marketing Approval in the European Union 3Kuvan Receives Marketing Approval in the European Union 4Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery 2... Proteolytic degradation is critical to the ... and regulatory proteins as important and ... metabolism, heat shock and stress response, ... receptors and ion channels, cell cycle ...
... Nucleic acid hybridization Preparation Reconstitution: ... BSA, 50 mg ficoll and ... 5 ml of water yields ... molecular biology Density: 1.00 g/mL ...
... joined forces with the Mickle Laboratory Engineering ... Chopper. This tissue sectioning system has been ... metabolic experiments and to be especially applicable ... biopsy or from small organs. Its special ...
... offer a full range of peptide synthesis ... include: Peptide synthesis, crude product (approximately ... purified product (70-95% pure) ... myristylation, phosphorylation, and rhodamine) Conjugations ...
Biology Products:Biology NavigationMedical Navigation